Abstract OT3-03-02: A phase 2, open-label, single-arm, multi-center study of talazoparib for neoadjuvant treatment of germlineBRCA1/2mutation patients with early-stage triple-negative breast cancer (TNBC)

2019 ◽  
Author(s):  
J Litton ◽  
F Symmans ◽  
K Gogineni ◽  
M Saltzman ◽  
ML Telli ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Early Stage ◽  
Neoadjuvant Treatment ◽  
Phase 2 ◽  
Open Label ◽  
Multi Center Study ◽  
Center Study

scholarly journals Dasatinib as a Single Agent in Triple-Negative Breast Cancer: Results of an Open-Label Phase 2 Study

2011 ◽  
Vol 17 (21) ◽  
pp. 6905-6913 ◽  
Author(s):  
Richard S. Finn ◽  
Carmelo Bengala ◽  
Nuhad Ibrahim ◽  
Henri Roché ◽  
Joseph Sparano ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Single Agent ◽  
Phase 2 ◽  
Open Label ◽  
Phase 2 Study ◽  
Open Label Phase

Abstract OT-32-01: A phase 2, open-label study of bintrafusp alfa monotherapy in patients withHMGA2-expressing triple-negative breast cancer

2021 ◽  
Author(s):  
Leisha A Emens ◽  
Margaret E. Gatti-Mays ◽  
Joyce O’Shaughnessy ◽  
Luc Dirix ◽  
Giovanni Faggioni ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Phase 2 ◽  
Open Label ◽  
Open Label Study ◽  
Label Study
Sign in / Sign up

Export Citation Format

Share Document